Early outlook on Merck’s tulisokibart in HS

Merck’s Phase 2b study of tulisokibart in moderate-to-severe hidradenitis suppurativa (HS) met its primary endpoint at week 16. HiSCR50—at least a 50% reduction in abscesses and inflammatory nodules—was achieved by 72% in the high-dose group and 64% in the medium-dose group, versus 35% on placebo.

The more stringent HiSCR75 response was 41% with high dose and 40% with medium dose, compared with 15% on placebo. Dermatology quality-of-life scores also improved in the high- and medium-dose groups.

Reported adverse-event rates were broadly similar across groups:
42.9% with high dose, 47.6% with medium dose, 52.4% with low dose and 40.9% with placebo. Serious adverse events were uncommon; no serious or opportunistic infections were reported.

The early physician-sentiment angle is that the efficacy signal looks promising enough to support further development, but it is not yet evidence of established clinical acceptance. The study was relatively small and lasted 16 weeks; Phase 3 results and longer-term safety will be important before judging tulisokibart’s place alongside existing HS treatments.

Merck has said it plans to advance tulisokibart into Phase 3 development for HS. Tulisokibart is investigational and targets TL1A; it is not approved for HS.

Sources:

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in ...

News releases - Merck.com

Investor relations - Merck.com

Merck's antibody impresses with 'highly competitive' data in ...

Merck's Tulisokibart Met Primary and Key Secondary ...

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

Merck's anti-TL1A antibody secures a win in ph. 2 ...

Merck posts 1 win, 1 loss in phase 2 inflammatory disease ...

Merck reports positive phase 2 trial results for HS treatment

News Release

Merck's Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis ...

MSD posts a victory and defeat for anti-TL1A in skin ...

Merck’s experimental skin disease drug succeeds in mid-stage study

Merck's $10.8B Prometheus deal delivers another win— ...

The Hidradenitis Suppurativa Therapeutic Pipeline